Context Therapeutics Inc. (CNTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.17
- As of
Kresmion compiles this page from CNTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Context Therapeutics Inc. (CNTX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-10.
See the full CNTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CNTX on one page. Preview it with sample data, then open it live with a free account.
Preview the CNTX dossierActive events for CNTX
- high13F: large increase
CITADEL ADVISORS LLC added +5644% to CNTX (2026Q3)
- mediumEarnings above estimates
Q3-2026: Beat consensus by 27.9%, EPS $-0.08 vs $-0.1109 estimate
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 90% of CNTX (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +469% to CNTX (2026Q2)
- medium13F: new position
TWO SIGMA INVESTMENTS, LP new position in CNTX
FREE, NO ACCOUNT
Every event on CNTX, as it fires
You are seeing 5 of 10 events recorded on CNTX since 2026-05-29.
The five above landed across 2 days. The other 5 were recorded on 3 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
CNTX positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q3 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 21077P108 · 2026Q3 | $299K | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 21077P108 · 2026Q3 | $291K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CNTX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
CNTX's 10-Q filed Nov 10, 2026 states:
As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on CNTX
CNTX against its peers
CNTX's return on equity of -59.7% ranks in the 78th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | CNTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 1.1M | n/a | 10 |
| Operating margin | n/a | -1927.8% | n/a | 10 |
| Net margin | n/a | -816.4% | n/a | 10 |
| Return on equity | -59.7% | -114.3% | 78 | 15 |
| 1 year | -85.8% | -65.0% | 15 | 16 |
Peers (19): PLUR, AKTX, ESLA, LPCN, ATYR, QNRX, NCEL, ACTU, ABOS, ALLR, KYNB, NEUP, BOLT, MRKR, JSPR, CKDXF, MCRB, KTTA, HEPA. Left out: FNCHQ (period gap), VICP (period gap), RADX (no annual filing), CTXR (no annual filing), BSEM (no annual filing), HOOK.D (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CNTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in CNTX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on CNTX in the last 180 days.
Upstream: SEC EDGAR filings for CNTX
Kresmion, "Context Therapeutics Inc. (CNTX) institutional holdings and SEC filings", data as of 2026-11-18, https://kresmion.com/research/CNTX. Upstream data: SEC EDGAR filings for CNTX.
Link to this data (HTML):
<a href="https://kresmion.com/research/CNTX">Context Therapeutics Inc. (CNTX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow CNTX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to CNTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.